J

Jagsonpal Pharmaceuticals Limited

JAGSNPHARM
Market snapshot · 2026-08-11 18:08 UTC

230.99

₹-1.98 (-0.85%)

MARKET CAP

₹1.52K Cr

STOCK P/E

34.4x

52W HIGH

₹264.50

52W LOW

₹155.00

BOOK VALUE

₹39.40

EPS

₹6.71

ROE

SECTOR

Health Care

DEBT/EQUITY

2.96

VOLUME

50,652

P/B RATIO

5.86x

PEG RATIO

Sector

Health Care

Themes

PharmaceuticalsMukul Agrawal PortfolioLincoln P Coelho Portfolio
D
Dividend
₹243.08₹223.24₹203.41₹183.57₹163.73VolumeDAug '25Sep '25Nov '25Jan '26Mar '26Apr '26Jun '26Aug '26

AI Summary

✦ Clartha

Forecast

Analyst targets, estimate history, and probabilistic forward ranges for JAGSNPHARM.

Coverage check

Price Forecast

Current
₹230.99
High Target
Median Target
Low Target
Now₹230.99Aug '25Now12M Target
Price history (1Y)
Analyst target range

Probabilistic Range

Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.

Time horizonRange ()Probability
3M₹180.87 - ₹276.0480%
6M₹160.29 - ₹291.4680%
12M₹132.52 - ₹308.6980%
Realized vol: +33.0% · Drift: -7.8%

Revenue Forecast

₹ Cr
Jun '26Current₹82.0
Sep 2026 ETrend estimate range
High₹83.9Base₹77.7Low₹71.5
Sep '25: ₹74.0 · Dec '25: ₹73.0 · Mar '26: ₹64.0 · Jun '26: ₹82.0 · Sep '26: ₹77.7 · Dec '26: ₹76.7
Sep '25Dec '25Mar '26Jun '26Sep '26 EDec '26 E74.073.064.082.077.776.7
PastCurrentTrend estimate: Low / Base / High

EPS Forecast

₹ / share
Jun '26Current₹2.00
Sep 2026 ETrend estimate range
High₹2.04Base₹1.83Low₹1.61
Sep '25: ₹1.89 · Dec '25: ₹1.64 · Mar '26: ₹1.31 · Jun '26: ₹2.00 · Sep '26: ₹1.83 · Dec '26: ₹1.58
Sep '25Dec '25Mar '26Jun '26Sep '26 EDec '26 E1.891.641.312.001.831.58
PastCurrentTrend estimate: Low / Base / High
Analyst price target unavailable from FMP/yfinance. Analyst pillar unavailable from FMP/yfinance.
Market Intelligence

Multi-factor synthesis of 5 key dimensions

Overall Outlook
Mixed
46%
Analyst Consensus
Unavailable

Analyst coverage unavailable

Mean upsideNot available

Fundamentals

Strong

Fundamentals institutional score is 75 using growth durability 74.8.

Valuation

Premium valuation

Valuation institutional score is 6 using relative multiple z-scores where peer dispersion is available.

Analyst Consensus

Unavailable

No usable analyst target or recommendation data was available.

Technical Structure

Mixed Momentum

Technicals institutional score is 50 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.

Market Sentiment

Unavailable

This data source has not been supplied for the decision payload.

Signal Summary

Market intelligence remains Mixed. fundamentals provide support, while valuation and technical structure remain considerations.

Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.

Fundamentals StrongValuation Premium valuationTechnical Structure Mixed Momentum

Key Data Points

Mean Target PriceUnavailable
Mean UpsideNot available
Technical Score50%
Fundamental Score75%
Data CoverageMedium

Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.

Valuation Metrics

Trading 19.4% above historical median. Valuation is declining — currently in the strongly overvalued zone (z-score: +0.98). Confidence: 78%.

Forward Valuation Outlook

Forward outlook is unavailable because live next-12-month estimate data is not available for this ticker right now.

P/E
Strongly Overvalued

5Y Average

24.43

Current

34.42

Overvalued

32.89

Undervalued

23.30

EV/EBITDA
Strongly Overvalued

5Y Average

16.46

Current

23.20

Overvalued

21.59

Undervalued

12.72

P/S
Strongly Overvalued

5Y Average

3.68

Current

5.18

Overvalued

4.82

Undervalued

2.84

Peers & Comparison

Sector: Health Care · Theme: Pharmaceuticals

Pharmaceuticals Peers1 peer
Avg P/E: 30.3x
CompanyRev. GrowthMarginP/Evs Avg52W Perf.
JEENA SIKHO LIFECARE LTD
JSLLPharmaceuticals
+28.8%27.8%
30.3x
Fair
0% vs avg
+0.1%
WHY THESE PEERS

JAGSONPAL PHARMACEUTICALS trades in line with peers (34.4x vs avg 30.3x), reflecting a fair valuation within the Pharmaceuticals cohort. Peers include JEENA SIKHO LIFECARE LTD — selected based on business model, industry classification, market cap similarity, and business theme alignment.

Financials

Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.

Latest revenue

₹82 CrJun 2026

Latest net profit

₹13 CrJun 2026

Latest EPS

₹2.00Jun 2026

Net margin

21.0%Jun 2026

Performance

Bars show revenue and net profit. The line shows net margin.

Rs crore + margin %
Q1 '26Q2 '26Q3 '26Q4 '26Q1 '270.0%6.0%12.0%18.0%24.0%0.00 Cr25 Cr50 Cr75 Cr100 Cr
  • Revenue
  • Net income
  • Net margin %

Earnings

Revenue is shown in crores. EPS is rupees per share.

Rs crore + Rs/share
Q1 '26Q2 '26Q3 '26Q4 '26Q1 '270.00 Cr25 Cr50 Cr75 Cr100 Cr₹0₹1₹1₹2₹2
  • Revenue
  • EPS

Revenue to profit conversion

Bridge from operating numbers to profit for the latest reported period.

Rs crore
RevenueExpensesDepreciationOtheradjustmentsOperatingprofitOther incomeInterestOtheradjustmentsProfitbefore taxTax & otherNet Profit0.00 Cr25 Cr50 Cr75 Cr100 Cr

Latest reported period: Jun 2026

Debt level and coverage

Debt, cash and free cash flow compared on the same crore scale.

Rs crore
Annual view
Mar 2022Mar 2023Mar 2024Mar 2025Mar 20260.00 Cr80 Cr160 Cr240 Cr320 Cr
  • Debt
  • Free cash flow
  • Cash & equivalents

Results

MetricJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales +60584743617574597674736482
Expenses +52494441515858506158575365
Operating Profit983310161691416161117
OPM %14%14%7%6%17%22%21%15%19%22%22%17%21%
Other Income +2232-2226333133
Interest0000000000000
Depreciation0000122222222
Profit before tax1010557153991417151218
Tax %26%25%25%22%25%25%17%24%25%25%25%25%25%
Net Profit +7744511327111311913
EPS in Rs1.141.140.600.540.811.734.820.991.621.891.641.312.00
Raw PDF

All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).

Shareholding Pattern

HolderJun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters +67.65%67.54%67.39%67.89%69.06%
FIIs +2.17%2.12%2.12%2.44%2.30%
DIIs +0.05%0.08%0.15%0.22%0.62%
Public +30.12%30.25%30.34%29.44%28.04%
Others0.01%0.01%0.01%
Jun 2026
Promoters +
FIIs +
DIIs +
Public +

Events Timeline

Announcement under Regulation 30 (LODR)-Earnings Call Transcript

Aug 04, 2026PDFCompany Reports Open

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

Jul 30, 2026PDFCompany Reports Open

Announcement under Regulation 30 (LODR)-Newspaper Publication

Jul 30, 2026PDFCompany Reports Open

Announcement under Regulation 30 (LODR)-Change in Management

Jul 29, 2026PDFCompany Reports Open

Corporate Action- Record Date: September 04, 2026

Jul 29, 2026PDFCompany Reports Open